Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure

NCT04983823 is registered in ClinicalTrials.gov with Baker Heart and Diabetes Institute as lead sponsor.

NCT NCT04983823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
Lead sponsor
Baker Heart and Diabetes Institute
Phase
Not applicable
Overall status
Recruiting
Start date
November 18, 2021
Completion date
December 30, 2025
Enrollment
820 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure